|
|
|
|
|||||
|
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost  |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
| PRTA | Garren Hideki | Chief Medical Officer | Mar 15 | Option Exercise | 24.90 | 12,000 | 298,800 | 12,000 | Mar 17 09:30 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Mar 15 | Sale | 48.41 | 12,000 | 580,936 | 0 | Mar 17 09:30 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Dec 01 | Option Exercise | 24.90 | 4,000 | 99,600 | 4,000 | Dec 02 09:30 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Dec 01 | Sale | 62.51 | 4,000 | 250,040 | 0 | Dec 02 09:30 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Nov 01 | Option Exercise | 24.90 | 4,000 | 99,600 | 4,000 | Nov 03 09:30 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Nov 01 | Sale | 61.89 | 4,000 | 247,575 | 0 | Nov 03 09:30 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Oct 03 | Option Exercise | 24.90 | 4,000 | 99,600 | 4,000 | Oct 05 09:46 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Oct 03 | Sale | 60.90 | 4,000 | 243,600 | 0 | Oct 05 09:46 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Sep 15 | Option Exercise | 24.90 | 4,000 | 99,600 | 4,000 | Sep 16 09:32 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Sep 15 | Sale | 30.00 | 4,000 | 120,000 | 0 | Sep 16 09:32 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Aug 01 | Option Exercise | 24.90 | 4,000 | 99,600 | 4,000 | Aug 03 09:39 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Aug 01 | Sale | 30.52 | 4,000 | 122,080 | 0 | Aug 03 09:39 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Jul 06 | Option Exercise | 24.90 | 8,000 | 199,200 | 8,000 | Jul 08 09:34 PM |
| PRTA | Garren Hideki | Chief Medical Officer | Jul 06 | Sale | 30.00 | 8,000 | 240,000 | 0 | Jul 08 09:34 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite